Current issues in the economics of vaccination against dengue

Expert Review of Vaccines

Volumn 15, Issue 4, 2016, Pages 519-528

  Tozan, Yesim ^a  

^a NEW YORK UNIVERSITY   (United States)

Author keywords

affordability; cost effectiveness; dengue; Dengue vaccination; dengue vaccines; developing countries; economic evaluation; low and middle income countries; national immunization programs; sustainability

Indexed keywords

DENGUE VACCINE;

CLINICAL DECISION MAKING; COST EFFECTIVENESS ANALYSIS; DENGUE; DEVELOPING COUNTRY; EVIDENCE BASED PRACTICE; HEALTH CARE PLANNING; HEALTH CARE POLICY; HUMAN; PRIORITY JOURNAL; PROGRAM SUSTAINABILITY; REVIEW; VACCINATION; COST BENEFIT ANALYSIS; DISEASE TRANSMISSION; ECONOMICS; ENDEMIC DISEASE; IMMUNOLOGY; ISOLATION AND PURIFICATION; PREVENTION AND CONTROL;

COST-BENEFIT ANALYSIS; DENGUE; DENGUE VACCINES; DISEASE TRANSMISSION, INFECTIOUS; ENDEMIC DISEASES; HUMANS; VACCINATION;

EID: 84952836914     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.2016.1129278     Document Type: Review

References (103)

1. WHO. Global strategy for dengue prevention and control 2012-2020. Geneva: WHO; 2012.
2. San Martín JL, Brathwaite O, Zambrano B., et al. The epidemiology of dengue in the Americas over the last three decades: a worrisome reality. Am J Trop Med Hyg. 2010; 82 (1): 128-135.
3. Gubler DJ. The global emergence/resurgence of arboviral diseases as public health problems. Arch Med Res. 2002; 33 (4): 330-342.
4. Ooi EE, Gubler DJ. Dengue in Southeast Asia: epidemiological characteristics and strategic challenges in disease prevention. Cad Saude Publica. 2009; 25 (Suppl 1): S115-124.
5. Guzman MG, Halstead SB, Artsob H., et al. Dengue: a continuing global threat. Nat Rev Microbiol. 2010; 8 (12 Suppl): S7-16.
6. Brathwaite Dick O, San Martin JL, Montoya RH., et al. The history of dengue outbreaks in the Americas. Am J Trop Med Hyg. 2012; 87 (4): 584-593.
7. Brady OJ, Gething PW, Bhatt S., et al. Refining the global spatial limits of dengue virus transmission by evidence-based consensus. PLoS Negl Trop Dis. 2012; 6 (8): e1760.
8. Vos T, Barber RM, Bell B., et al. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. The Lancet. 2015; 386 (9995): 743-800.
9. Gubler DJ. Epidemic dengue/dengue hemorrhagic fever as a public health, social and economic problem in the 21st century. Trends Microbiol. 2002; 10 (2): 100-103.
10. Horstick O, Tozan Y, Wilder-Smith A., et al. Reviewing dengue: still a neglected tropical disease? PLoS Negl Trop Dis. 2015; 9 (4): e0003632.
11. Peeling RW, Artsob H, Pelegrino JL., et al. Evaluation of diagnostic tests: dengue. Nat Rev Micro. 2010; 8 (12 Suppl): S30-8.
12. Gubler DJ. Dengue and dengue hemorrhagic fever. Clin Microbiol Rev. 1998; 11 (3): 480-496.
13. Kalayanarooj S. Standardized clinical management: evidence of reduction of dengue haemorrhagic fever case-fatality rate in Thailand. Dengue Bull. 1999; 23: 10-17.
14. WHO. Dengue-Guidelines for diagnosis, treatment, prevention and control. Geneva: World Health Organization; 2009.
15. Stahl H-C, Butenschoen VM, Tran HT., et al. Cost of dengue outbreaks: literature review and country case studies. BMC Public Health. 2013; 13: 1048.
16. Beatty ME, Beutels P, Meltzer MI., et al. Health economics of dengue: a systematic literature review and expert panels assessment. Am J Trop Med Hyg. 2011; 84 (3): 473-488.
17. Suaya JA, Shepard DS, Siqueira JB., et al. Cost of dengue cases in eight countries in the Americas and Asia: a prospective study. Am J Trop Med Hyg. 2009; 80 (5): 846-855.
18. Shepard DS, Undurraga EA, Halasa YA., et al. Economic and disease burden of dengue in Southeast Asia. PLoS Negl Trop Dis. 2013; 7 (2): e2055.
19. Torres JR, Castro J. The health and economic impact of dengue in Latin America. Cad Saude Publica. 2007; 23 (Suppl 1): S23-31.
20. Horstick O, Runge-Ranzinger S, Nathan MB., et al. Dengue vector-control services: how do they work? A systematic literature review and country case studies. Trans R Soc Trop Med Hyg. 2010; 104 (6): 379-386.
21. Erlanger TE, Keiser J, Utzinger J. Effect of dengue vector control interventions on entomological parameters in developing countries: a systematic review and meta-analysis. Med Vet Entomol. 2008; 22 (3): 203-221.
22. Gratz NG. The control of dengue vectors. In: Halstead SB., editor. Dengue. Vol. 5. London: Imperial College Press; 2008. p. 361-387.
23. Simmons CP, Farrar JJ, Van Vinh Chau N., et al. Dengue. New England J Med. 2012; 366 (15): 1423-1432.
24. Villar L, Dayan GH, Arredondo-Garcia JL., et al. Efficacy of a tetravalent dengue vaccine in children in Latin America. N Engl J Med. 2015; 372 (2): 113-123.
25. Capeding MR, Tran NH, Hadinegoro SR., et al. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. Lancet. 2014; 384 (9951): 1358-1365.
26. Sabchareon A, Wallace D, Sirivichayakul C., et al. Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. The Lancet. 2012; 380 (9853): 1559-1567.
27. Hadinegoro SR, Arredondo-Garcia JL, Capeding MR., et al. Efficacy and long-term safety of a dengue vaccine in regions of endemic disease. N Engl J Med. 2015; 373 (13): 1195-1206.
28. DeRoeck D, Deen J, Clemens JD. Policymakers views on dengue fever/dengue haemorrhagic fever and the need for dengue vaccines in four southeast Asian countries. Vaccine. 2003; 22 (1): 121-129.
29. Zorlu G, Fleck F. Dengue vaccine roll-out: getting ahead of the game. Bull World Health Organ. 2011; 89 (7): 476-477.
30. Lee J-S, Mogasale V, Lim JK., et al. A multi-country study of the household willingness-to-pay for dengue vaccines: household surveys in Vietnam, Thailand, and Colombia. PLoS Negl Trop Dis. 2015; 9 (6): e0003810.
31. Douglas DL, DeRoeck DA, Mahoney RT., et al. Will dengue vaccines be used in the public sector and if so, how? Findings from an 8-country survey of policymakers and opinion leaders. PLoS Negl Trop Dis. 2013; 7 (3): e2127.
32. Palanca-Tan R. The demand for a dengue vaccine: a contingent valuation survey in Metro Manila. Vaccine. 2008; 26 (7): 914-923.
33. The World Bank. World development report 1993: investing in health. Oxford: Oxford University Press; 1993.
34. Ehreth J. The global value of vaccination. Vaccine. 2003; 21 (7-8): 596-600.
35. Bloom DE. The value of vaccination. Adv Exp Med Biol. 2011; 697: 1-8.
36. Greenwood B. The contribution of vaccination to global health: past, present and future. Phil Trans R Soc B. 2014; 369: 20130433.
37. Batt K, Fox-Rushby JA, Castillo-Riquelme M. The costs, effects and cost-effectiveness of strategies to increase coverage of routine immunizations in low- and middle-income countries: systematic review of the grey literature. Bull World Health Organ. 2004; 82 (9): 689-696.
38. Gandhi G, Lydon P. Updating the evidence base on the operational costs of supplementary immunization activities for current and future accelerated disease control, elimination and eradication efforts. BMC Public Health. 2014; 14: 67.
39. Brooks A, Smith TA, De Savigny D., et al. Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. BMC Public Health. 2012; 380: 1559-1567.
40. Ozawa S, Mirelman A, Stack ML., et al. Cost-effectiveness and economic benefits of vaccines in low- and middle-income countries: a systematic review. Vaccine. 2012; 31 (1): 96-108.
41. Brenzel L, Claquin P. Immunization programs and their costs. Soc Sci Med. 1994; 39 (4): 527-536.
42. Creese AL, Henderson RH. Cost-benefit analysis and immunization programmes in developing countries. Bull World Health Organ. 1980; 58 (3): 491-497.
43. Gandhi G, Lydon P, Cornejo S., et al. Projections of costs, financing, and additional resource requirements for low- and lower middle-income country immunization programs over the decade, 2011-2020. Vaccine. 2013; 31 (Suppl 2): B137-148.
44. WHO. Principles and considerations for adding a vaccine to a national immunization programme: from decision to implementation to monitoring. Geneva: World Health Organization; 2014.
45. Zaffran M, Vandelaer J, Kristensen D., et al. The imperative for stronger vaccine supply and logistics systems. Vaccine. 2013; 31 (Suppl 2): B73-80.
46. Saxenian H, Hecht R, Kaddar M., et al. Overcoming challenges to sustainable immunization financing: early experiences from GAVI graduating countries. Health Policy Plan. 2015; 30 (2): 197-205.
47. Kim SY, Goldie SJ. Cost-effectiveness analyses of vaccination programmes: a focused review of modelling approaches. Pharmacoeconomics. 2008; 26 (3): 191-215.
48. Beutels P, Van Doorslaer E, Van Damme P., et al. Methodological issues and new developments in the economic evaluation of vaccines. Expert Rev Vaccines. 2003; 2 (5): 649-660.
49. Brisson M, Edmunds WJ. Economic evaluation of vaccination programs: the impact of herd-immunity. Medical Decision Making. 2003; 23 (1): 76-82.
50. Johansson MA, Hombach J, Cummings DA. Models of the impact of dengue vaccines: a review of current research and potential approaches. Vaccine. 2011; 29 (35): 5860-5868.
51. Andraud M, Hens N, Marais C., et al. Dynamic epidemiological models for dengue transmission: a systematic review of structural approaches. PLoS One. 2012; 7 (11): e49085.
52. Wilder-Smith A. Dengue vaccines: dawning at last? Lancet. 2014; 384 (9951): 1327-1329.
53. Rodriguez-Barraquer I, Mier-y-Teran-Romero L, Schwartz IB., et al. Potential opportunities and perils of imperfect dengue vaccines. Vaccine. 2014; 32 (4): 514-520.
54. Chao DL, Halstead SB, Halloran ME., et al. Controlling dengue with vaccines in Thailand. PLoS Negl Trop Dis. 2012; 6 (10): e1876.
55. Coudeville L, Garnett GP. Transmission dynamics of the four dengue serotypes in southern Vietnam and the potential impact of vaccination. PLoS One. 2012; 7 (12): e51244.
56. Halstead SB. Neutralization and antibody-dependent enhancement of dengue viruses. Adv Virus Res. 2003; 60: 421-467.
57. Shepard DS, Suaya JA, Halstead SB., et al. Cost-effectiveness of a pediatric dengue vaccine. Vaccine. 2004; 22 (9-10): 1275-1280.
58. Lee BY, Connor DL, Kitchen SB., et al. Economic value of dengue vaccine in Thailand. Am J Trop Med Hyg. 2011; 84 (5): 764-772.
59. Shepard DS, Suaya JA. Cost-effectiveness of a dengue vaccine in Southeast Asia and Panama: preliminary estimates. In: Preedy V, Watson R., editors. Handbook of disease burdens and quality of life measures. New York: Springer; 2010. p. 1281-1296.
60. Carrasco LR, Lee LK, Lee VJ., et al. Economic impact of dengue illness and the cost-effectiveness of future vaccination programs in Singapore. PLoS Negl Trop Dis. 2011; 5 (12): e1426.
61. Durham DP, Ndeffo Mbah ML, Medlock J., et al. Dengue dynamics and vaccine cost-effectiveness in Brazil. Vaccine. 2013; 31 (37): 3957-3961.
62. Yothasamut J, Tantivess S, Teerawattananon Y. Using economic evaluation in policy decision-making in Asian countries: mission impossible or mission probable? Value Health. 2009; 12 (Suppl 3): S26-30.
63. Iglesias CP, Drummond MF, Rovira J., et al. Health-care decision-making processes in Latin America: problems and prospects for the use of economic evaluation. Int J Technol Assess Health Care. 2005; 21 (1): 1-14.
64. Hutubessy R, Henao AM, Namgyal P., et al. Results from evaluations of models and cost-effectiveness tools to support introduction decisions for new vaccines need critical appraisal. BMC Med. 2011; 9: 55.
65. Andrus JK, Toscano CM, Lewis M., et al. A model for enhancing evidence-based capacity to make informed policy decisions on the introduction of new vaccines in the Americas: PAHOs ProVac initiative. Public Health Rep. 2007; 122 (6): 811-816.
66. Jit M, Levin C, Brisson M., et al. Economic analyses to support decisions about HPV vaccination in low- and middle-income countries: a consensus report and guide for analysts. BMC Med. 2013; 11: 23.
67. Mahoney R. The introduction of new vaccines into developing countries. V: will we lose a decade or more in the introduction of dengue vaccines to developing countries? Vaccine. 2014; 32 (8): 904-908.
68. Mahoney RT, Francis DP, Frazatti-Gallina NM., et al. Cost of production of live attenuated dengue vaccines: a case study of the Instituto Butantan, Sao Paulo, Brazil. Vaccine. 2012; 30 (32): 4892-4896.
69. Thisyakorn U, Capeding MR, Goh DY., et al. Preparing for dengue vaccine introduction in ASEAN countries: recommendations from the first ADVA regional workshop. Expert Rev Vaccines. 2014; 13 (5): 581-587.
70. Torres M. Impact of an outbreak of dengue fever: a case study from Rural Puerto Rico. Hum Organ. 1997; 56 (1): 19-27.
71. Khun S, Manderson L. Health seeking and access to care for children with suspected dengue in Cambodia: an ethnographic study. BMC Public Health. 2007; 7 (1): 262.
72. Hadisoemarto PF, Castro MC. Public acceptance and willingness-to-pay for a future dengue vaccine: a community-based survey in Bandung, Indonesia. PLoS Negl Trop Dis. 2013; 7 (9): e2427.
73. Levin A, Kaddar M. Role of the private sector in the provision of immunization services in low- and middle-income countries. Health Policy Plan. 2011; 26 (suppl 1): i4-i12.
74. Levine R, Mitchell V. Immunization financing options: a resource for policymakers. In: Force GFT., editor. GAVI financing task force. Geneva: GAVI Alliance; 2007.
75. Sanofi P. From research to production: a quest to make dengue preventable. [cited 2015 Nov 16]. Available from: https://lehub.sanofi.com/en/innovation-en/industrial-production-dengue-preventable/.
76. Dengue Vaccine Initiative. DVI September 2015 newsletter. [cited 2015 Nov 13]. Available from: http://www.denguevaccines.org/dvi-september-2015-newsletter.
77. Martin Del Campo J, Greenberg A, Morgan G., et al. Generating supply and demand estimates to inform dengue vaccine introduction in Mexico: preliminary results of a strategic demand forecast. 64th Annual Meeting of the American Society of Tropical Medicine and Hygiene; Philadelphia, PA; Abstract number: 1417; 2015
78. Garcia CA, Wilsin-Barthes M, Coelho GE., et al. Estimating teh supply and demand for a Butantan dengue vaccine using different introduction strategies in Brazil. 64th Annual Meeting of the American Society of Tropical Medicine and Hygiene; Philadelphia, PA; Abstract number: 1415; 2015.
79. Brenzel L, Wolfson L, Foz-Rushby J., et al. Vaccine preventable diseases. In: Jamison D, Breman J, Meashem A., et al., editors. Disease control priorities in developing countries. 2nd ed. Washington: The World Bank; 2006.
80. Levin CE, Van Minh H, Odaga J., et al. Delivery cost of human papillomavirus vaccination of young adolescent girls in Peru, Uganda and Viet Nam. Bull World Health Organ. 2013; 91 (8): 585-592.
81. Kaufmann JR, Miller R, Cheyne J. Vaccine supply chains need to be better funded and strengthened, or lives will be at risk. Health Aff. 2011; 30 (6): 1113-1121.
82. Mvundura M, Kien VD, Nga NT., et al. How much does it cost to get a dose of vaccine to the service delivery location? Empirical evidence from Vietnams expanded program on immunization. Vaccine. 2014; 32 (7): 834-838.
83. GAVI Alliance, editor. GAVI Alliance progress report. Geneva: GAVI Alliance; 2014.
84. Brenzel L, Politi C. Historical analysis of the comprehensive multi-year plans (2004-2015). Geneva: WHO; 2012.
85. Lydon P, Levine R, Makinen M., et al. Introducing new vaccines in the poorest countries: what did we learn from the GAVI experience with financial sustainability? Vaccine. 2008; 26 (51): 6706-6716.
86. Kaddar M, Lydon P, Levine R. Financial challenges of immunization: a look at GAVI. Bull World Health Organ. 2004; 82 (9): 697-702.
87. GAVI Alliance. Countries approved for support. Results and Evidence. [cited 2005 Sep 20]. Available from: http://www.gavi.org/results/countries-approved-for-support/
88. Dengue Vaccine Initiative. Development of dengue vaccines: a review of the status and future considerations. Baltimore (MD): Dengue Vaccine Initiative; 2015.
89. Pan American Health Organization. Immunization: ProVac. [cited 2015 Sep 16]. Available from: http://www.paho.org/provac/.
90. Andrus JK, Jauregui B, De Oliveira LH., et al. Challenges to building capacity for evidence-based new vaccine policy in developing countries. Health Aff (Millwood). 2011; 30 (6): 1104-1112.
91. Torresi J, Tapia-Conyer R, Margolis H. Preparing for dengue vaccine introduction: recommendations from the 1st dengue v2V International Meeting. PLoS Negl Trop Dis. 2013; 7 (9): e2261.
92. Waddington C. Does earmarked donor funding make it more or less likely that developing countries will allocate their resources towards programmes that yield the greatest health benefits? Bull World Health Organ. 2004; 82 (9): 703-706. discussion 706-708
93. Zuber PL, El-Ziq I, Kaddar M., et al. Sustaining GAVI-supported vaccine introductions in resource-poor countries. Vaccine. 2011; 29 (17): 3149-3154.
94. Duclos P, Ortynsky S, Abeysinghe N., et al. Monitoring of progress in the establishment and strengthening of national immunization technical advisory groups. Vaccine. 2012; 30 (50): 7147-7152.
95. SIVAC Initiative. Supporting national independent immunization and vaccine advisory committees. [cited 2005 Sep 20]. Available from: http://sivacinitiative.org/.
96. Kamara L, Milstien JB, Patyna M., et al. Strategies for financial sustainability of immunization programs: a review of the strategies from 50 national immunization program financial sustainability plans. Vaccine. 2008; 26 (51): 6717-6726.
97. Lam SK, Burke D, Capeding MR., et al. Preparing for introduction of a dengue vaccine: recommendations from the 1st dengue v2V Asia-pacific meeting. Vaccine. 2011; 29 (51): 9417-9422.
98. Thomas SJ, Rothman AL. Trials and tribulations on the path to developing a dengue vaccine. Vaccine. 2015 Jun 27; 33 (Suppl 4): D24-31.
99. Kane MA, Brooks A. New immunization initiatives and progress toward the global control of hepatitis B. Curr Opin Infect Dis. 2002; 15 (5): 465-469.
100. Deogaonkar R, Hutubessy R, Van Der Putten I., et al. Systematic review of studies evaluating the broader economic impact of vaccination in low and middle income countries. BMC Public Health. 2012; 12 (1): 878.
101. Barnighausen T, Bloom DE, Cafiero-Fonseca ET., et al. Valuing vaccination. Proc Natl Acad Sci U S A. 2014; 111 (34): 12313-12319.
102. Ozawa S, Stack ML, Bishai DM., et al. During the decade of vaccines, the lives of 6.4 million children valued at $231 billion could be saved. Health Aff (Millwood). 2011; 30 (6): 1010-1020.
103. Barnighausen T, Bloom DE, Cafiero ET., et al. Valuing the broader benefits of dengue vaccination, with a preliminary application to Brazil. Semin Immunol. 2013; 25 (2): 104-113.